Feed Top Reports Pricing

⌘K

07:52:06·66d

ANALYSTRatingvia Quantisnow

AtriCure downgraded by Oppenheimer

ByQuantisnow·Wall Street's wire, on your screen.

ATRC· AtriCure Inc.

Health Care

Original source

This insight was delivered by Quantisnow - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATRC (AtriCure Inc.) and more on Quantisnow.

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

ATRC
AtriCure Inc.
Health Care

Recent analyst ratings

Feb 18UpdateOppenheimer-
Feb 11UpdateAnalyst$36.00
Dec 17UpdateAnalyst$40.00
Apr 23UpdateOppenheimer$32.00
Oct 23UpdateJMP Securities$60.00
Sep 29UpdateUBS$56.00

Related

PR11d
AtriCure to Announce First Quarter 2026 Financial Results
SEC19d
SEC Form DEFA14A filed by AtriCure Inc.
SEC19d
SEC Form DEF 14A filed by AtriCure Inc.
SEC30d
Amendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.
INSIDER40d
Chief Scientific Officer Doraiswamy Vinayak sold $149,150 worth of shares (5,000 units at $29.83), decreasing direct ownership by 5% to 96,875 units (SEC Form 4)
INSIDER44d
Director White Robert S. exercised 10,000 shares at a strike of $14.99, increasing direct ownership by 9% to 122,174 units (SEC Form 4)
INSIDER47d
President, CEO, & Director Carrel Michael H gifted 6,000 shares, decreasing direct ownership by 0.76% to 778,498 units (SEC Form 4)
INSIDER53d
Chief Scientific Officer Doraiswamy Vinayak was granted 45,588 shares and covered exercise/tax liability with 15,585 shares, increasing direct ownership by 42% to 101,875 units (SEC Form 4)

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Refer a trader25%Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022